PTX 10.6% 4.2¢ prescient therapeutics limited

Ann: PTX Receives Two US Patents Covering PTX-200, page-10

  1. 10,354 Posts.
    lightbulb Created with Sketch. 1131
    Quote from announcement - "Prescient CEO and Managing Director, Steven Yatomi-Clarke said, “We are very pleased with the overall progress of PTX-200. Early clinical data has been strong and underlines the potential of PTX-200 as a unique targeted therapy. The allowance of two additional US patents for PTX-200 is another important step in building out a strong product pipeline of novel personalised therapies for cancer. Prescient’s pipeline has never been stronger, nor deeper.”
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.2¢
Change
-0.005(10.6%)
Mkt cap ! $33.82M
Open High Low Value Volume
4.7¢ 4.7¢ 4.2¢ $79.18K 1.795M

Buyers (Bids)

No. Vol. Price($)
3 30362 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 50053 2
View Market Depth
Last trade - 15.36pm 26/08/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.